Dexcom (DXCM) Net Cash Flow Growth (3y) (2013 - 2026)
Dexcom (DXCM) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.13 Bn | 175.83 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 108.98 Bn | 99.76 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.45 Bn | 67.00 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.01 Bn | 44.34 Bn | 1.29 Bn | -87.88% |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.01 Bn | 1.98 Bn | -65.12% |
| 7 | Dexcom | 28.25 Bn | 27.13 Bn | 750.30 Mn | 129.29% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | -48.90% |
| 10 | Steris | 21.55 Bn | 21.11 Bn | 697.10 Mn | 33.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 129.29% |
| Dec 31, 2025 | -145.09% |
| Sep 30, 2025 | 190.79% |
| Jun 30, 2025 | 115.96% |
| Mar 31, 2025 | 42.34% |
| Dec 31, 2024 | 78.48% |
| Sep 30, 2024 | -46.40% |
| Jun 30, 2024 | -40.57% |
| Mar 31, 2024 | 76.02% |
| Dec 31, 2023 | -37.20% |
| Sep 30, 2023 | -80.04% |
| Jun 30, 2023 | 131.44% |
| Mar 31, 2023 | -28.96% |
| Dec 31, 2022 | -48.42% |
| Sep 30, 2022 | 54.20% |
| Jun 30, 2022 | 26.85% |
| Mar 31, 2022 | -62.19% |
| Dec 31, 2021 | -35.91% |
| Sep 30, 2021 | 62.59% |
| Jun 30, 2021 | 77.13% |